Adipose Tissue Gene Analysis for Obesity Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting and diagnosing obesity-related diseases like diabetes and cardiovascular diseases are imprecise, relying on indirect markers such as BMI, and lack reliable molecular markers for identifying immature adipose tissue, which is a risk factor for these conditions.
Innovation Solution
A method involving the analysis of gene expression levels of HMGA2 and PPAR-gamma in adipose tissue samples, combined with body fat percentage, to categorize individuals into specific risk groups, allowing for a more precise prognosis and diagnosis of obesity and associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If BMI is used as the indicator for obesity assessment, then the assessment is simple and widely applicable, but the precision of disease risk prediction is insufficient
Solution Approach 1:
The patent segments the assessment into multiple components: BMI calculation combined with gene expression analysis (HMGA2 and PPAR-gamma) to create a more comprehensive risk stratification system. This segmentation allows maintaining the simplicity of BMI while adding molecular precision through genetic markers.
Solution Approach 2:
The patent creates a composite assessment model that integrates anthropometric data (BMI) with molecular biology data (gene expression levels). This composite approach combines the advantages of both simple physical measurement and precise molecular characterization to improve overall prediction accuracy.
2Ease of manufacture
If traditional markers are used for disease prediction, then the method is simple to implement, but the reliability of diagnosis is insufficient
Solution Approach 1:
The patent merges traditional clinical markers (BMI, body fat percentage) with molecular markers (gene expression levels of HMGA2 and PPAR-gamma) into a unified diagnostic approach. This combination maintains ease of implementation while significantly improving diagnostic reliability through multiple independent assessment dimensions.
Solution Approach 2:
The patent introduces new parameters (gene expression levels) to the traditional assessment framework, transforming the diagnostic approach from purely phenotypic to include genotypic information. This parameter expansion enhances reliability without completely abandoning the simplicity of traditional methods.
3Measurement precision
If gene expression analysis is added to BMI assessment, then the precision of risk assessment is improved, but the complexity of the method increases
Solution Approach 1:
The patent extracts specific key genes (HMGA2 and PPAR-gamma) that are most relevant to adipose tissue development and disease risk, rather than analyzing the entire genome. This extraction approach maintains high precision while reducing complexity by focusing only on the most informative genetic markers.
Solution Approach 2:
The patent adds a molecular biology dimension to the traditional anthropometric assessment, creating a two-dimensional evaluation framework (physical + molecular). This dimensional expansion improves precision while organizing complexity into distinct, manageable layers of assessment.
Data Source
AI summary
The invention relates to a method for the prognosis of adiposity and the prognosis and/or diagnosis of a disease selected from the group consisting of diabetes, cardiovascular diseases and metabolic syndrome